FAP and neoplasm: The tetravalent bispecific mAb RG7386 (RO874813, a FAP mAb coupled with death receptor 5 (DR5) agonist), which binds FAP+ fibroblasts and DR5+ tumour cells, induced tumour regression in a colorectal cancer mouse model [138].